drugset / Trial / NCT02315495

Combining Saxagliptin and Acarbose to Improve Postprandial Glycaemia in Type 2 Diabetes

NCT02315495

Phase 3 Completed 22 enrolled Zilin Sun
RandomizedCrossoverOpen-labelTreatment

Summary

The proposed study is designed to evaluate (i) the effects of saxagliptin, with or without acarbose, on gastric emptying, postprandial glycaemia, and plasma intact GLP-1, insulin, C-peptide and glucagon after a high carbohydrate meal, and (ii) whether the magnitude of the effects of saxagliptin and/or acarbose is related to the rate of gastric emptying, in patients with type 2 diabetes.

Timeline

Start
2015-04-03
Primary completion
2016-08-26
Completion
2016-08-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Acarbose Unknown 100 mg
Subject SAXAGLIPTIN ANHYDROUS Small molecule 5 mg